Related Experiment Video
Updated: Aug 20, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
Yasutaka Mamiya1, Hidenori Kanazawa, Yuu Kimura
1Third Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Abstract:
The aim of this prospective study was to investigate the incidence, clinical features and the short- and long-term clinical course of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) in Japanese patients. Eighty-seven consecutive patients with liver cirrhosis presenting with complications of portal hypertension underwent TIPS. The mean follow-up period after TIPS was 866 days. During the follow-up, HE occurred in 52% of patients throughout the follow-up period. The cumulative incidence of post-TIPS HE was 50.5+/-5.6% at 1 year (mean+/-S.D.). Most cases (89%) occurring within 7 days were easily controlled by the conventional therapy. Only two patients developed severe chronic HE, which was treated by reducing the shunt diameter. Older age, indication for TIPS (ascites) and higher retention rate of indocyanine green at 15min were identified as risk factors for post-TIPS HE. During long-term follow-up, the incident of post-TIPS HE decreased among survivals. The cumulative survival rate was similar in patients with or without post-TIPS HE. Our results indicate that post-TIPS HE are a frequent complication, particularly in the early months after TIPS. However, it can be easily managed in the majority of patients. The development of post-TIPS HE is not associated with poor prognosis in TIPS patients.
Related Concept Videos
Hepatic Encephalopathy
Portal Hypertension
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

